Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Articles by Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Latest Updated Articles
Management of Adverse Effects in R/R HER2+ mBCSeptember 23rd 2020
FDA-approved Therapies for Relapsed/Refractory HER2+ mBCSeptember 23rd 2020
Practical Management of Early Stage HER2+ Breast CancerSeptember 23rd 2020
HER2-targeted Therapy: Routes of AdministrationSeptember 23rd 2020
Advertisement
Advertisement
Trending on OncLive
1
Next-Generation CTLA-4 Targeting Frames Post-Immunotherapy Squamous NSCLC Management
2
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
3
Carotuximab Plus Apalutamide Improves PFS in mCRPC
4
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
5